SIMPATHIC
SIMPATHIC is a method that helps find new uses for existing drugs, especially for rare diseases, by comparing how diseases are similar in terms of their symptoms and underlying biology.
At a glance
Use when
Exploring new treatments for rare diseases, especially when traditional drug development is not feasible; when molecular and clinical data are available for comparison across diseases
Avoid when
When disease mechanisms are poorly understood or data is insufficient; when pathological similarity does not translate to therapeutic response
Inputs
Molecular pathology data (e.g., genomics, transcriptomics), clinical phenotype data, disease-drug interaction databases, known drug profiles
Outputs
Ranked list of repurposable drugs, disease similarity maps, mechanistic rationale for drug-disease matches
How it works
SIMPATHIC (Similarity-based Pathology Informed Combination therapy) is a framework developed within the REPO4EU project that enables drug repurposing by identifying pathological similarities—both clinical and molecular—across diseases. It leverages multi-omics data and clinical phenotypes to map disease relationships and predict effective drug candidates based on shared pathological mechanisms.
- Project
- REPO4EU
- Funding
- Horizon Europe
- Project status
- Ongoing
- HTA domains
- Clinical Effectiveness, Patient and Social Aspects, Aspects Beyond HTA
- Assumptions
- Diseases with similar molecular or clinical pathology may respond to similar treatments; shared pathological mechanisms can be identified and leveraged across diseases
- Strengths
- Enables drug repurposing with reduced development time and cost; particularly useful for rare diseases with limited therapeutic options; integrates multiple data types for robust predictions
- Limitations
- Dependent on quality and availability of molecular and clinical data; may miss novel mechanisms not captured by existing similarity metrics; validation in clinical settings may be limited
- Also known as
- Similarity-based Pathology Informed Combination therapy
Questions this answers
- › Which existing drugs could be effective for a rare disease based on shared pathology?
- › How similar are two diseases in terms of molecular and clinical features?
- › Can pathological mechanisms inform rational drug repurposing?
- › What evidence supports the biological plausibility of repurposing a drug?
- › Which patient subgroups might benefit from a repurposed drug based on disease similarity?
- › How can we prioritize drug candidates for rare diseases with limited data?
References & sources
Related methods
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.